Patents by Inventor Anker Steen Jorgensen

Anker Steen Jorgensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 11Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds
    Publication number: 20100120743
    Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
    Type: Application
    Filed: December 17, 2009
    Publication date: May 13, 2010
    Applicant: High Point Pharmaceuticals, LLC
    Inventors: Anette Gundertofte, Anker Steen Jorgensen, Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen, Inge Thoger Christensen, John Paul Kilburn
  • 11?-hydroxysteroid dehydrogenase type 1 active compounds
    Patent number: 7700583
    Abstract: A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the activity of 11?-hydroxy-steroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, e.g. the metabolic syndrome.
    Type: Grant
    Filed: October 6, 2005
    Date of Patent: April 20, 2010
    Assignee: High Point Pharmaceuticals, LLC
    Inventors: Anette Gundertofte, Anker Steen Jorgensen, Gita Camilla Tejlgaard Kampen, Henrik Sune Andersen, Inge Thoger Christensen, Kilburn Paul John
  • PHARMACEUTICAL USE OF SUBSTITUTED AMIDES
    Publication number: 20090124598
    Abstract: The use of substituted amides for modulating the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11?HSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    Type: Application
    Filed: November 1, 2006
    Publication date: May 14, 2009
    Inventors: Henrik Sune Andersen, Anker Steen Jorgensen, John Paul Kilburn, Gita Camilla Tejlgaard Kampen, Soren Ebdrup
  • Glucagon antagonists/inverse agonists
    Patent number: 6953812
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: October 11, 2005
    Assignee: Novo Nordisk, Inc.
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Non-peptide GLP-1 agonists
    Patent number: 6927214
    Abstract: Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 9, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Min Teng, Larry Kenneth Truesdale, Dilip Bhumralkar, Dan Kiel, Michael D. Johnson, Christine Thomas, Anker Steen Jorgensen, Peter Madsen, Preben Houlberg Olesen, Liselotte Bjerre Knudsen, Ingrid Vivika Petterson, Johannes Cornelis de Jong, Carsten Behrens, Janos Tibor Kodra, Jesper Lau
  • Glucagon antagonists/inverse agonists
    Patent number: 6821960
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: November 23, 2004
    Assignee: Noyo Nordisk Pharmaceuticals, Inc.
    Inventors: Anker Steen Jørgensen, Peter Madsen
  • Novel glucagon antagonists
    Publication number: 20040152750
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 15, 2003
    Publication date: August 5, 2004
    Inventors: Janos Tibor Kodra, Carsten Behrens, Peter Madsen, Anker Steen Jorgensen, Inger Thoger Christensen
  • Glucagon antagonists
    Patent number: 6762318
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Grant
    Filed: December 3, 2002
    Date of Patent: July 13, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Glucagon antagonists/inverse agonists
    Publication number: 20040024045
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Application
    Filed: February 24, 2003
    Publication date: February 5, 2004
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Novel glucagon antagonists
    Publication number: 20030236292
    Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.
    Type: Application
    Filed: December 3, 2002
    Publication date: December 25, 2003
    Inventors: Janos Tibor Kodra, Peter Madsen, Jesper Lau, Anker Steen Jorgensen, Inge Thoger Christensen
  • Glucagon antagonists/inverse agonists
    Patent number: 6562807
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: May 13, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Glucagon antagonists/inverse agonists
    Publication number: 20030027849
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: November 16, 2001
    Publication date: February 6, 2003
    Inventors: Anker Steen Jorgensen, Peter Madsen
  • Glucagon antagonists/inverse agonists
    Publication number: 20020143186
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.
    Type: Application
    Filed: June 22, 2001
    Publication date: October 3, 2002
    Inventors: Anker Steen Jorgensen, Inge Thoger Christensen, Janos Tibor Kodra, Christian Sams, Carsten Behrens, Peter Madsen, Jesper Lau
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6365609
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: April 2, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Patent number: 6362205
    Abstract: Described are substituted cyanoenamines of formula I wherein Z, R1, R2 and R3 are defined in the description, compositions thereof and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: March 26, 2002
    Assignee: Novo Nordisk A/S
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Publication number: 20010056188
    Abstract: Disclosed are substituted cyanoenamines, compositions containing these compounds, and methods for preparing these compounds. These compounds are useful in the treatment of diseases of the central nervous system, the cardiovascular system, the pulmonary system, the gastrointestinal system and the endocrinologic system.
    Type: Application
    Filed: March 16, 2001
    Publication date: December 27, 2001
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Substituted 3,3-diamino-2-propenenitriles, their preparation and use
    Publication number: 20010025111
    Abstract: Substituted cyanoenamines of the general formula I 1
    Type: Application
    Filed: May 3, 2001
    Publication date: September 27, 2001
    Inventors: John Bondo Hansen, Tina Moller Tagmose, John Patrick Mogensen, Florencio Zaragoza Dorwald, Anker Steen Jorgensen
  • Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
    Patent number: 6080754
    Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: June 27, 2000
    Assignee: Novo Nordisk A/S
    Inventors: Anker Steen Jorgensen, Poul Jacobsen, Lise Brown Christiansen, Paul Stanley Bury, Anders Kanstrup
  • Pyrrolo [2,1,5-cd] indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
    Patent number: 6075036
    Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: June 13, 2000
    Assignees: Novo Nordisk, Karo Bio AB
    Inventors: Anker Steen Jorgensen, Poul Jacobsen, Lise Brown Christiansen, Paul Stanley Bury, Anders Kanstrup